Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
JCO Precision Oncology|January 21, 2026
Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern Unites StatesJenny O'Brien, Ryne C Ramaker, Ashley Moyer, et al.
NPJ Breast Cancer|March 30, 2023
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecanLaura Alder, Dario Trapani, Claire Bradbury, et al.
Journal of Neuro-Oncology|June 16, 2025
Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockadeJazlyn A Seidel, Laura Alder, April K S Salama, et al.
The Lancet. Oncology|March 29, 2023
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials ConferenceRifaquat Rahman, Mei-Yin C Polley, Laura Alder, et al.
Frontiers in Oncology|July 11, 2025
Young lung cancer: from diagnosis to survivorshipNarjust Florez, Lauren Kiel, Rebekah Kaufman, et al.
Neuro-Oncology Advances|January 7, 2026
Impact of systemic therapy after stereotactic radiosurgery in patients with limited brain-only metastasisJamiluddin J Qazi, Amanda E D Van Swearingen, David J Carpenter, et al.
Research Square|July 3, 2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 StudyEziafa Oduah, Jhanelle Gray, Thomas Stinchcombe, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANSBingnan Zhang, Laura Alder, Samuel Rosner, et al.
NPJ Precision Oncology|March 14, 2026
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancerPaolo Tarantino, Se-Eun Kim, Melissa E Hughes, et al.
Pageof 2